english

研究業績

原著論文

2025

  1. Iwatsuki-Horimoto, K., Uraki, R., Ito, M., Wang, T., Guan, L., Halfmann, P., Eisfeld, A., Neumann, G., Yamayoshi, S. & Kawaoka, Y. Transmission of bovine H5N1 virus in a hamster model. J Virol 99, e0014725 (2025). https://doi.org/10.1128/jvi.00147-25
  2. Uraki, R., Ito, M., Kiso, M., Iwatsuki-Horimoto, K., Endo, M., Yamayoshi, S. & Kawaoka, Y. An XBB.1.5-based inactivated SARS-CoV-2 vaccine partially protects against XBB.1.5 and JN.1 strains in hamsters. Npj Viruses 3, 7 (2025). https://doi.org/10.1038/s44298-025-00096-y
  3. Uraki, R., Kiso, M., Ito, M., Yamayoshi, S., Halfmann, P., Jain, S., Suthar, M. S., Lopes, T. J. S., Jounai, N., Miyaji, K., Takeshita, F. & Kawaoka, Y. An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant. eBioMedicine 117, 105794 (2025). https://doi.org/10.1016/j.ebiom.2025.105794
  4. Kiso, M., Uraki, R., Yamayoshi, S. & Kawaoka, Y. Efficacy of baloxavir marboxil against bovine H5N1 virus in mice. Nat Commun 16, 5356 (2025). https://doi.org/10.1038/s41467-025-60791-5
  5. Furusawa, Y., Kiso, M., Uraki, R., Sakai-Tagawa, Y., Nagai, H., Koga, M., Kashima, Y., Hojo, M., Iwamoto, N., Iwatsuki-Horimoto, K., Ohmagari, N., Suzuki, Y., Yotsuyanagi, H., Halfmann, P. J., Kamitani, W., Yamayoshi, S. & Kawaoka, Y. Amino acid substitutions in NSP6 and NSP13 of SARS-CoV-2 contribute to superior virus growth at low temperatures. J Virol 99, e0221724 (2025). https://doi.org/10.1128/jvi.02217-24
  6. Kuroda, M., Halfmann, P. J., Uraki, R., Yamayoshi, S., Kim, T., Armbrust, T. A., Spyra, S., Dahn, R., Babujee, L. & Kawaoka, Y. SARS-CoV-2 virus lacking the envelope and membrane open-reading frames as a vaccine platform. Nat Commun 16, 4453 (2025). https://doi.org/10.1038/s41467-025-59533-4

2024

  1. Gu, C., Maemura, T., Guan, L., Eisfeld, A. J., Biswas, A., Kiso, M., Uraki, R., Ito, M., Trifkovic, S., Wang, T., Babujee, L., Presler, R., Jr., Dahn, R., Suzuki, Y., Halfmann, P. J., Yamayoshi, S., Neumann, G. & Kawaoka, Y. A human isolate of bovine H5N1 is transmissible and lethal in animal models. Nature 636, 711-718 (2024). https://doi.org/10.1038/s41586-024-08254-7
  2. Kuwata, T., Kaku, Y., Biswas, S., Matsumoto, K., Shimizu, M., Kawanami, Y., Uraki, R., Okazaki, K., Minami, R., Nagasaki, Y., Nagashima, M., Yoshida, I., Sadamasu, K., Yoshimura, K., Ito, M., Kiso, M., Yamayoshi, S., Imai, M., Ikeda, T., Sato, K., Toyoda, M., Ueno, T., Inoue, T., Tanaka, Y., Kimura, K. T., Hashiguchi, T., Sugita, Y., Noda, T., Morioka, H., Kawaoka, Y., Matsushita, S. & Genotype to Phenotype Japan, C. Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case. eBioMedicine 110, 105439 (2024). https://doi.org/10.1016/j.ebiom.2024.105439
  3. Uraki, R., Imai, M., Ito, M., Yamayoshi, S., Kiso, M., Jounai, N., Miyaji, K., Iwatsuki-Horimoto, K., Takeshita, F. & Kawaoka, Y. An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants. NPJ Vaccines 9, 4 (2024). https://doi.org/10.1038/s41541-023-00800-0
  4. Halfmann, P. J., Iwatsuki-Horimoto, K., Kuroda, M., Hirata, Y., Yamayoshi, S., Iida, S., Uraki, R., Ito, M., Ueki, H., Furusawa, Y., Sakai-Tagawa, Y., Kiso, M., Armbrust, T., Spyra, S., Maeda, K., Wang, Z., Imai, M., Suzuki, T. & Kawaoka, Y. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters. Commun Biol 7, 331 (2024). https://doi.org/10.1038/s42003-024-06015-w
  5. Chiba, S., Kiso, M., Yamada, S., Someya, K., Onodera, Y., Yamaguchi, A., Matsunaga, S., Uraki, R., Iwatsuki-Horimoto, K., Yamayoshi, S., Takeshita, F. & Kawaoka, Y. An mRNA vaccine candidate encoding H5HA clade 2.3.4.4b protects mice from clade 2.3.2.1a virus infection. NPJ Vaccines 9, 189 (2024). https://doi.org/10.1038/s41541-024-00988-9
  6. Kiso, M., Uraki, R., Yamayoshi, S., Imai, M. & Kawaoka, Y. Drug susceptibility and the potential for drug-resistant SARS-CoV-2 emergence in immunocompromised animals. iScience 27, 110729 (2024). https://doi.org/10.1016/j.isci.2024.110729

2023

  1. Minohara, K., Imai, M., Matoba, T., Wing, J. B., Shime, H., Odanaka, M., Uraki, R., Kawakita, D., Toyama, T., Takahashi, S., Morita, A., Murakami, S., Ohkura, N., Sakaguchi, S., Iwasaki, S. & Yamazaki, S. Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer. Cancer Sci 114, 1256-1269 (2023). https://doi.org/10.1111/cas.15698
  2. Uraki, R., Ito, M., Kiso, M., Yamayoshi, S., Iwatsuki-Horimoto, K., Furusawa, Y., Sakai-Tagawa, Y., Imai, M., Koga, M., Yamamoto, S., Adachi, E., Saito, M., Tsutsumi, T., Otani, A., Kikuchi, T., Yotsuyanagi, H., Halfmann, P. J., Pekosz, A. & Kawaoka, Y. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate. Lancet Infect Dis 23, 402-403 (2023). https://doi.org/10.1016/S1473-3099(23)00070-1
  3. Uraki, R., Kiso, M., Iwatsuki-Horimoto, K., Yamayoshi, S., Ito, M., Chiba, S., Sakai-Tagawa, Y., Imai, M., Kashima, Y., Koga, M., Fuwa, N., Okumura, N., Hojo, M., Iwamoto, N., Kato, H., Nakajima, H., Ohmagari, N., Yotsuyanagi, H., Suzuki, Y. & Kawaoka, Y. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Cell Rep 42, 113580 (2023). https://doi.org/10.1016/j.celrep.2023.113580
  4. Uraki, R., Imai, M. & Kawaoka, Y. Antiviral Agents against Omicron Subvariant BA.4.6 In Vitro. Reply. N Engl J Med 388, e12 (2023). https://doi.org/10.1056/NEJMc2216611
  5. Nakayama, T., Azegami, T., Kiso, M., Imai, M., Uraki, R., Hayashi, K., Hishikawa, A., Yoshimoto, N., Nakamichi, R., Sugita-Nishimura, E., Yoshida-Hama, E., Kawaoka, Y. & Itoh, H. Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection. Sci Rep 13, 3103 (2023). https://doi.org/10.1038/s41598-023-30305-8
  6. Uraki, R., Ito, M., Furusawa, Y., Yamayoshi, S., Iwatsuki-Horimoto, K., Adachi, E., Saito, M., Koga, M., Tsutsumi, T., Yamamoto, S., Otani, A., Kiso, M., Sakai-Tagawa, Y., Ueki, H., Yotsuyanagi, H., Imai, M. & Kawaoka, Y. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis 23, 30-32 (2023). https://doi.org/10.1016/S1473-3099(22)00816-7
  7. Imai, M., Ito, M., Kiso, M., Yamayoshi, S., Uraki, R., Fukushi, S., Watanabe, S., Suzuki, T., Maeda, K., Sakai-Tagawa, Y., Iwatsuki-Horimoto, K., Halfmann, P. J. & Kawaoka, Y. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N Engl J Med 388, 89-91 (2023). https://doi.org/10.1056/NEJMc2214302
  8. Halfmann, P. J., Uraki, R., Kuroda, M., Iwatsuki-Horimoto, K., Yamayoshi, S., Ito, M. & Kawaoka, Y. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters. eBioMedicine 93, 104677 (2023). https://doi.org/10.1016/j.ebiom.2023.104677
  9. Kiso, M., Furusawa, Y., Uraki, R., Imai, M., Yamayoshi, S. & Kawaoka, Y. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. Nat Commun 14, 3952 (2023). https://doi.org/10.1038/s41467-023-39704-x
  10. Ishizaka, A., Koga, M., Mizutani, T., Uraki, R., Yamayoshi, S., Iwatsuki-Horimoto, K., Yamamoto, S., Imai, M., Tsutsumi, T., Suzuki, Y., Kawaoka, Y. & Yotsuyanagi, H. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination. Virol J 20, 146 (2023). https://doi.org/10.1186/s12985-023-02113-z
  11. Kiso, M., Yamayoshi, S., Iida, S., Furusawa, Y., Hirata, Y., Uraki, R., Imai, M., Suzuki, T. & Kawaoka, Y. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. Nat Commun 14, 4231 (2023). https://doi.org/10.1038/s41467-023-40018-1
  12. Uraki, R., Iida, S., Halfmann, P. J., Yamayoshi, S., Hirata, Y., Iwatsuki-Horimoto, K., Kiso, M., Ito, M., Furusawa, Y., Ueki, H., Sakai-Tagawa, Y., Kuroda, M., Maemura, T., Kim, T., Mine, S., Iwamoto, N., Li, R., Liu, Y., Larson, D., Fukushi, S., Watanabe, S., Maeda, K., Wang, Z., Ohmagari, N., Theiler, J., Fischer, W., Korber, B., Imai, M., Suzuki, T. & Kawaoka, Y. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. Nat Commun 14, 1620 (2023). https://doi.org/10.1038/s41467-023-37059-x
  13. Furusawa, Y., Kiso, M., Iida, S., Uraki, R., Hirata, Y., Imai, M., Suzuki, T., Yamayoshi, S. & Kawaoka, Y. In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters. eBioMedicine 91, 104561 (2023). https://doi.org/10.1016/j.ebiom.2023.104561
  14. Uraki, R..., Ito, M., Kiso, M., Yamayoshi, S., Iwatsuki-Horimoto, K., Sakai-Tagawa, Y., Furusawa, Y., Imai, M., Koga, M., Yamamoto, S., Adachi, E., Saito, M., Tsutsumi, T., Otani, A., Kashima, Y., Kikuchi, T., Yotsuyanagi, H., Suzuki, Y. & Kawaoka, Y. Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1. Lancet Infect Dis 23, 525-526 (2023). https://doi.org/10.1016/S1473-3099(23)00132-9
  15. Uraki, R..., Ito, M., Kiso, M., Yamayoshi, S., Iwatsuki-Horimoto, K., Sakai-Tagawa, Y., Imai, M., Koga, M., Yamamoto, S., Adachi, E., Saito, M., Tsutsumi, T., Otani, A., Kashima, Y., Kikuchi, T., Theiler, J., Yotsuyanagi, H., Suzuki, Y., Korber, B. & Kawaoka, Y. Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate. Lancet Reg Health West Pac 34, 100777 (2023). https://doi.org/10.1016/j.lanwpc.2023.100777
  16. Uraki, R..., Ito, M., Kiso, M., Yamayoshi, S., Iwatsuki-Horimoto, K., Sakai-Tagawa, Y., Imai, M., Koga, M., Yamamoto, S., Adachi, E., Saito, M., Tsutsumi, T., Otani, A., Fukushi, S., Watanabe, S., Suzuki, T., Kikuchi, T., Yotsuyanagi, H., Maeda, K. & Kawaoka, Y. Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate. iScience 26, 108147 (2023). https://doi.org/10.1016/j.isci.2023.108147
  17. Kingstad-Bakke, B., Cleven, T., Bussan, H., Yount, B. L., Jr., Uraki, R..., Iwatsuki-Horimoto, K., Koga, M., Yamamoto, S., Yotsuyanagi, H., Park, H., Mishra, J. S., Kumar, S., Baric, R. S., Halfmann, P. J., Kawaoka, Y. & Suresh, M. Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine. JCI Insight 8 (2023). https://doi.org/10.1172/jci.insight.172510

2022

  1. Uraki, R., Kiso, M., Imai, M., Yamayoshi, S., Ito, M., Fujisaki, S., Takashita, E., Ujie, M., Furusawa, Y., Yasuhara, A., Iwatsuki-Horimoto, K., Sakai-Tagawa, Y., Watanabe, S., Hasegawa, H. & Kawaoka, Y. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Nat Microbiol 7, 1252-1258 (2022). https://doi.org/10.1038/s41564-022-01170-4
  2. Uraki, R., Halfmann, P. J., Iida, S., Yamayoshi, S., Furusawa, Y., Kiso, M., Ito, M., Iwatsuki-Horimoto, K., Mine, S., Kuroda, M., Maemura, T., Sakai-Tagawa, Y., Ueki, H., Li, R., Liu, Y., Larson, D., Fukushi, S., Watanabe, S., Maeda, K., Pekosz, A., Kandeil, A., Webby, R. J., Wang, Z., Imai, M., Suzuki, T. & Kawaoka, Y. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature 612, 540-545 (2022). https://doi.org/10.1038/s41586-022-05482-7
  3. Takashita, E., Yamayoshi, S., Halfmann, P., Wilson, N., Ries, H., Richardson, A., Bobholz, M., Vuyk, W., Maddox, R., Baker, D. A., Friedrich, T. C., O’Connor, D. H., Uraki, R., Ito, M., Sakai-Tagawa, Y., Adachi, E., Saito, M., Koga, M., Tsutsumi, T., Iwatsuki-Horimoto, K., Kiso, M., Yotsuyanagi, H., Watanabe, S., Hasegawa, H., Imai, M. & Kawaoka, Y. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6. N Engl J Med 387, 2094-2097 (2022). https://doi.org/10.1056/NEJMc2211845
  4. Uraki, R., Kiso, M., Iida, S., Imai, M., Takashita, E., Kuroda, M., Halfmann, P. J., Loeber, S., Maemura, T., Yamayoshi, S., Fujisaki, S., Wang, Z., Ito, M., Ujie, M., Iwatsuki-Horimoto, K., Furusawa, Y., Wright, R., Chong, Z., Ozono, S., Yasuhara, A., Ueki, H., Sakai-Tagawa, Y., Li, R., Liu, Y., Larson, D., Koga, M., Tsutsumi, T., Adachi, E., Saito, M., Yamamoto, S., Hagihara, M., Mitamura, K., Sato, T., Hojo, M., Hattori, S. I., Maeda, K., Valdez, R., team, I. s., Okuda, M., Murakami, J., Duong, C., Godbole, S., Douek, D. C., Maeda, K., Watanabe, S., Gordon, A., Ohmagari, N., Yotsuyanagi, H., Diamond, M. S., Hasegawa, H., Mitsuya, H., Suzuki, T. & Kawaoka, Y. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature 607, 119-127 (2022). https://doi.org/10.1038/s41586-022-04856-1
  5. Halfmann, P. J., Iida, S., Iwatsuki-Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S. M., Darling, T. L., Joshi, A., Loeber, S., Singh, G., Foster, S. L., Ying, B., Case, J. B., Chong, Z., Whitener, B., Moliva, J., Floyd, K., Ujie, M., Nakajima, N., Ito, M., Wright, R., Uraki, R., Warang, P., Gagne, M., Li, R., Sakai-Tagawa, Y., Liu, Y., Larson, D., Osorio, J. E., Hernandez-Ortiz, J. P., Henry, A. R., Ciuoderis, K., Florek, K. R., Patel, M., Odle, A., Wong, L. R., Bateman, A. C., Wang, Z., Edara, V. V., Chong, Z., Franks, J., Jeevan, T., Fabrizio, T., DeBeauchamp, J., Kercher, L., Seiler, P., Gonzalez-Reiche, A. S., Sordillo, E. M., Chang, L. A., van Bakel, H., Simon, V., Consortium Mount Sinai Pathogen Surveillance study, g., Douek, D. C., Sullivan, N. J., Thackray, L. B., Ueki, H., Yamayoshi, S., Imai, M., Perlman, S., Webby, R. J., Seder, R. A., Suthar, M. S., Garcia-Sastre, A., Schotsaert, M., Suzuki, T., Boon, A. C. M., Diamond, M. S. & Kawaoka, Y. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687-692 (2022). https://doi.org/10.1038/s41586-022-04441-6
  6. Takashita, E., Yamayoshi, S., Fukushi, S., Suzuki, T., Maeda, K., Sakai-Tagawa, Y., Ito, M., Uraki, R., Halfmann, P., Watanabe, S., Takeda, M., Hasegawa, H., Imai, M. & Kawaoka, Y. Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N Engl J Med 387, 1236-1238 (2022). https://doi.org/10.1056/NEJMc2209952 

2021

  1. Uraki, R., Imai, M., Ito, M., Shime, H., Odanaka, M., Okuda, M., Kawaoka, Y. & Yamazaki, S. Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens. PLoS Pathog 17, e1010085 (2021). https://doi.org/10.1371/journal.ppat.1010085
  2. Shime, H., Odanaka, M., Tsuiji, M., Matoba, T., Imai, M., Yasumizu, Y., Uraki, R., Minohara, K., Watanabe, M., Bonito, A. J., Fukuyama, H., Ohkura, N., Sakaguchi, S., Morita, A. & Yamazaki, S. Reply to Slominski et al.: UVB irradiation induces proenkephalin(+) regulatory T cells with a wound-healing function. Proc Natl Acad Sci U S A 118 (2021). https://doi.org/10.1073/pnas.2021919118

2020

  1. Shime, H., Odanaka, M., Tsuiji, M., Matoba, T., Imai, M., Yasumizu, Y., Uraki, R., Minohara, K., Watanabe, M., Bonito, A. J., Fukuyama, H., Ohkura, N., Sakaguchi, S., Morita, A. & Yamazaki, S. Proenkephalin(+) regulatory T cells expanded by ultraviolet B exposure maintain skin homeostasis with a healing function. Proc Natl Acad Sci U S A 117, 20696-20705 (2020). https://doi.org/10.1073/pnas.2000372117
  2. Wang, Y., Uraki, R., Hwang, J. & Fikrig, E. TRiC/CCT Complex, a Binding Partner of NS1 Protein, Supports the Replication of Zika Virus in Both Mammalians and Mosquitoes. Viruses 12 (2020). https://doi.org/10.3390/v12050519

2019

  1. Uraki, R., Hastings, A. K., Brackney, D. E., Armstrong, P. M. & Fikrig, E. AgBR1 antibodies delay lethal Aedes aegypti-borne West Nile virus infection in mice. NPJ Vaccines 4, 23 (2019). https://doi.org/10.1038/s41541-019-0120-x
  2. Okuda, M., Yamayoshi, S., Uraki, R., Ito, M., Hamabata, T. & Kawaoka, Y. Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018. Viruses 11 (2019). https://doi.org/10.3390/v11040321
  3. Hastings, A. K., Uraki, R., Gaitsch, H., Dhaliwal, K., Stanley, S., Sproch, H., Williamson, E., MacNeil, T., Marin-Lopez, A., Hwang, J., Wang, Y., Grover, J. R. & Fikrig, E. Aedes aegypti NeSt1 Protein Enhances Zika Virus Pathogenesis by Activating Neutrophils. J Virol 93 (2019). https://doi.org/10.1128/JVI.00395-19
  4. Uraki, R., Hastings, A. K., Marin-Lopez, A., Sumida, T., Takahashi, T., Grover, J. R., Iwasaki, A., Hafler, D. A., Montgomery, R. R. & Fikrig, E. Aedes aegypti AgBR1 antibodies modulate early Zika virus infection of mice. Nat Microbiol 4, 948-955 (2019). https://doi.org/10.1038/s41564-019-0385-x
  5. Hastings, A. K., Hastings, K., Uraki, R., Hwang, J., Gaitsch, H., Dhaliwal, K., Williamson, E. & Fikrig, E. Loss of the TAM Receptor Axl Ameliorates Severe Zika Virus Pathogenesis and Reduces Apoptosis in Microglia. iScience 13, 339-350 (2019). https://doi.org/10.1016/j.isci.2019.03.003

2019年以前の論文

  1. Ano, Y., Sakudo, A., Uraki, R., Sato, Y., Kono, J., Sugiura, K., Yokoyama, T., Itohara, S., Nakayama, H., Yukawa, M. & Onodera, T. Enhanced enteric invasion of scrapie agents into the villous columnar epithelium via maternal immunoglobulin. Int J Mol Med 26, 845-851 (2010). https://doi.org/10.3892/ijmm_00000533
  2. Ano, Y., Sakudo, A., Kimata, T., Uraki, R., Sugiura, K. & Onodera, T. Oxidative damage to neurons caused by the induction of microglial NADPH oxidase in encephalomyocarditis virus infection. Neurosci Lett 469, 39-43 (2010). https://doi.org/10.1016/j.neulet.2009.11.040
  3. Uraki, R., Sakudo, A., Ando, S., Kitani, H. & Onodera, T. Enhancement of phagocytotic activity by prion protein in PrP-deficient macrophage cells. Int J Mol Med 26, 527-532 (2010). https://doi.org/10.3892/ijmm_00000495
  4. Uraki, R., Sakudo, A., Michibata, K., Ano, Y., Kono, J., Yukawa, M. & Onodera, T. Blocking of FcR suppresses the intestinal invasion of scrapie agents. PLoS One 6, e17928 (2011). https://doi.org/10.1371/journal.pone.0017928
  5. Kiso, M., Takano, R., Sakabe, S., Katsura, H., Shinya, K., Uraki, R., Watanabe, S., Saito, H., Toba, M., Kohda, N. & Kawaoka, Y. Protective efficacy of orally administered, heat-killed Lactobacillus pentosus b240 against influenza A virus. Sci Rep 3, 1563 (2013). https://doi.org/10.1038/srep01563
  6. Kobayashi, H., Iwatsuki-Horimoto, K., Kiso, M., Uraki, R., Ichiko, Y., Takimoto, T. & Kawaoka, Y. A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine. Vaccine 31, 6239-6246 (2013). https://doi.org/10.1016/j.vaccine.2013.10.029
  7. Uraki, R., Kiso, M., Shinya, K., Goto, H., Takano, R., Iwatsuki-Horimoto, K., Takahashi, K., Daniels, R. S., Hungnes, O., Watanabe, T. & Kawaoka, Y. Virulence determinants of pandemic A(H1N1)2009 influenza virus in a mouse model. J Virol 87, 2226-2233 (2013). https://doi.org/10.1128/JVI.01565-12
  8. Uraki, R., Kiso, M., Iwatsuki-Horimoto, K., Fukuyama, S., Takashita, E., Ozawa, M. & Kawaoka, Y. A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges. J Virol 87, 7874-7881 (2013). https://doi.org/10.1128/JVI.00076-13
  9. Watanabe, T., Kiso, M., Fukuyama, S., Nakajima, N., Imai, M., Yamada, S., Murakami, S., Yamayoshi, S., Iwatsuki-Horimoto, K., Sakoda, Y., Takashita, E., McBride, R., Noda, T., Hatta, M., Imai, H., Zhao, D., Kishida, N., Shirakura, M., de Vries, R. P., Shichinohe, S., Okamatsu, M., Tamura, T., Tomita, Y., Fujimoto, N., Goto, K., Katsura, H., Kawakami, E., Ishikawa, I., Watanabe, S., Ito, M., Sakai-Tagawa, Y., Sugita, Y., Uraki, R., Yamaji, R., Eisfeld, A. J., Zhong, G., Fan, S., Ping, J., Maher, E. A., Hanson, A., Uchida, Y., Saito, T., Ozawa, M., Neumann, G., Kida, H., Odagiri, T., Paulson, J. C., Hasegawa, H., Tashiro, M. & Kawaoka, Y. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501, 551-555 (2013). https://doi.org/10.1038/nature12392
  10. Muramoto, Y., Shoemaker, J. E., Le, M. Q., Itoh, Y., Tamura, D., Sakai-Tagawa, Y., Imai, H., Uraki, R., Takano, R., Kawakami, E., Ito, M., Okamoto, K., Ishigaki, H., Mimuro, H., Sasakawa, C., Matsuoka, Y., Noda, T., Fukuyama, S., Ogasawara, K., Kitano, H. & Kawaoka, Y. Disease severity is associated with differential gene expression at the early and late phases of infection in nonhuman primates infected with different H5N1 highly pathogenic avian influenza viruses. J Virol 88, 8981-8997 (2014). https://doi.org/10.1128/JVI.00907-14
  11. Yamayoshi, S., Yamada, S., Fukuyama, S., Murakami, S., Zhao, D., Uraki, R., Watanabe, T., Tomita, Y., Macken, C., Neumann, G. & Kawaoka, Y. Virulence-affecting amino acid changes in the PA protein of H7N9 influenza A viruses. J Virol 88, 3127-3134 (2014). https://doi.org/10.1128/JVI.03155-13
  12. Uraki, R., Das, S. C., Hatta, M., Kiso, M., Iwatsuki-Horimoto, K., Ozawa, M., Coban, C., Ishii, K. J. & Kawaoka, Y. Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine. Vaccine 32, 5295-5300 (2014). https://doi.org/10.1016/j.vaccine.2014.07.079
  13. Uraki, R., Piao, Z., Akeda, Y., Iwatsuki-Horimoto, K., Kiso, M., Ozawa, M., Oishi, K. & Kawaoka, Y. A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia. J Infect Dis 212, 1939-1948 (2015). https://doi.org/10.1093/infdis/jiv341
  14. Yamayoshi, S., Fukuyama, S., Yamada, S., Zhao, D., Murakami, S., Uraki, R., Watanabe, T., Tomita, Y., Neumann, G. & Kawaoka, Y. Amino acids substitutions in the PB2 protein of H7N9 influenza A viruses are important for virulence in mammalian hosts. Sci Rep 5, 8039 (2015). https://doi.org/10.1038/srep08039
  15. Jurado, K. A., Simoni, M. K., Tang, Z., Uraki, R., Hwang, J., Householder, S., Wu, M., Lindenbach, B. D., Abrahams, V. M., Guller, S. & Fikrig, E. Zika virus productively infects primary human placenta-specific macrophages. JCI Insight 1 (2016). https://doi.org/10.1172/jci.insight.88461
  16. Ui, H., Yamayoshi, S., Uraki, R., Kiso, M., Oishi, K., Murakami, S., Mimori, S. & Kawaoka, Y. Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus. Vaccine 35, 1892-1897 (2017). https://doi.org/10.1016/j.vaccine.2017.02.041
  17. Hastings, A. K., Yockey, L. J., Jagger, B. W., Hwang, J., Uraki, R., Gaitsch, H. F., Parnell, L. A., Cao, B., Mysorekar, I. U., Rothlin, C. V., Fikrig, E., Diamond, M. S. & Iwasaki, A. TAM Receptors Are Not Required for Zika Virus Infection in Mice. Cell Rep 19, 558-568 (2017). https://doi.org/10.1016/j.celrep.2017.03.058
  18. Yasuhara, A., Yamayoshi, S., Soni, P., Takenaga, T., Kawakami, C., Takashita, E., Sakai-Tagawa, Y., Uraki, R., Ito, M., Iwatsuki-Horimoto, K., Sasaki, T., Ikuta, K., Yamada, S. & Kawaoka, Y. Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies. Sci Rep 7, 17735 (2017). https://doi.org/10.1038/s41598-017-17986-8
  19. Uraki, R., Hwang, J., Jurado, K. A., Householder, S., Yockey, L. J., Hastings, A. K., Homer, R. J., Iwasaki, A. & Fikrig, E. Zika virus causes testicular atrophy. Sci Adv 3, e1602899 (2017). https://doi.org/10.1126/sciadv.1602899
  20. Uraki, R., Jurado, K. A., Hwang, J., Szigeti-Buck, K., Horvath, T. L., Iwasaki, A. & Fikrig, E. Fetal Growth Restriction Caused by Sexual Transmission of Zika Virus in Mice. J Infect Dis 215, 1720-1724 (2017). https://doi.org/10.1093/infdis/jix204
  21. Yamayoshi, S., Uraki, R., Ito, M., Kiso, M., Nakatsu, S., Yasuhara, A., Oishi, K., Sasaki, T., Ikuta, K. & Kawaoka, Y. A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release. eBioMedicine 17, 182-191 (2017). https://doi.org/10.1016/j.ebiom.2017.03.007
  22. Kiso, M., Iwatsuki-Horimoto, K., Yamayoshi, S., Uraki, R., Ito, M., Nakajima, N., Yamada, S., Imai, M., Kawakami, E., Tomita, Y., Fukuyama, S., Itoh, Y., Ogasawara, K., Lopes, T. J. S., Watanabe, T., Moncla, L. H., Hasegawa, H., Friedrich, T. C., Neumann, G. & Kawaoka, Y. Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques. J Infect Dis 216, 582-593 (2017). https://doi.org/10.1093/infdis/jix296
  23. Yamayoshi, S., Ito, M., Uraki, R., Sasaki, T., Ikuta, K. & Kawaoka, Y. Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human. J Infect 76, 177-185 (2018). https://doi.org/10.1016/j.jinf.2017.12.004
  24. Soni, P., Yasuhara, A., Takenaga, T., Iwatsuki-Horimoto, K., Uraki, R., Ito, M., Sasaki, T., Ikuta, K., Yamayoshi, S. & Kawaoka, Y. Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus. J Vet Med Sci 80, 1020-1024 (2018). https://doi.org/10.1292/jvms.18-0146
  25. Uraki, R., Hastings, A. K., Gloria-Soria, A., Powell, J. R. & Fikrig, E. Altered vector competence in an experimental mosquito-mouse transmission model of Zika infection. PLoS Negl Trop Dis 12, e0006350 (2018). https://doi.org/10.1371/journal.pntd.0006350
  26. Yamayoshi, S., Yasuhara, A., Ito, M., Uraki, R. & Kawaoka, Y. Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus. J Clin Virol 108, 105-111 (2018). https://doi.org/10.1016/j.jcv.2018.09.016
  27. Wu, N. C., Yamayoshi, S., Ito, M., Uraki, R., Kawaoka, Y. & Wilson, I. A. Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene. Cell Host Microbe 24, 569-578 e564 (2018). https://doi.org/10.1016/j.chom.2018.09.010

総説

  1. Uraki, R., Korber, B., Diamond, MS., Kawaoka, Y. SARS-CoV-2 variants: biology, pathogenicity, immunity and control. Nat Rev Microbiol. (2025) https://doi.org/10.1038/s41579-025-01255-x
  2. Uraki, R. & Kawaoka, Y. Host glycolipids in SARS-CoV-2 entry. Nat Chem Biol.18,6-7 (2022) https://doi.org/10.1038/s41589-021-00923-2

東京大学 新世代感染症センター

GMP教育分野 浦木研究室

〒108-8639　東京都港区白金台4-6-1

Department of GMP Education and ImmunoVirology, URAKI Lab

The University of Tokyo Pandemic Preparedness
Infection and Advanced Research

4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639 Japan

Copyright © Uraki Lab
トップへ戻るボタン